Not recruiting
Diffuse large B-cell lymphoma+1
Not recruitingRegistered drugNo placebo
Study on the Effectiveness and Safety of Odronextamab Compared to Standard Treatment in Adults with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
Registered drugNo placebo
- Disease:Diffuse large B-cell lymphomaNon-Hodgkin's lymphoma unspecified histology aggressive recurrent
- Substances:CarboplatinCisplatin+7
Countries:
Austria
Austria- Participants:18–64 years · 65+ years
- Substances:Carboplatin
- Sponsor:Regeneron Pharmaceuticals Inc.



